**Case Report**

**Dexamethasone Associated ST Elevation Myocardial Infarction Four Days after an Unremarkable Coronary Angiogram—Another Reason for Cautious Use of Steroids: A Case Report and Review of the Literature**

Mohamed Shokr,1 Ahmed Rashed,2 Kusum Lata,2 and Ashok Kondur2

1Internal Medicine Department, Detroit Medical Center/Wayne State University, Detroit, MI 48201, USA
2Cardiology Department, Detroit Medical Center/Wayne State University, Detroit, MI 48201, USA

Correspondence should be addressed to Mohamed Shokr; mshokr@med.wayne.edu

Received 3 May 2016; Accepted 20 June 2016

Academic Editor: Antoniode Padua Mansur

Copyright © 2016 Mohamed Shokr et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Drug induced myocardial infarction is a known entity with different forms of steroids linked to coronary artery disease (CAD) either through promoting its traditional risk factors, inducing coronary spasm, or by other unidentified mechanisms. Dexamethasone is known to promote an atherogenic and hypercoagulable state. We report a case of a 75-year-old woman who had ST elevation myocardial infarction (STEMI) associated with dexamethasone use just 4 days following an angiogram showing minor luminal irregularities.

1. Introduction

ST elevation myocardial infarction is a substantial health problem with estimated 30-day mortality between 2.5 and 10% [1]. Nontraditional risk factors play a significant role in more than 50% of CAD cases [2]. More than 150 drugs were reported as possible causes of acute MI. Betamethasone, methylprednisolone, and dexamethasone were among 39 drugs highlighted as prime suspects that can cause acute MI [3]. We report a case of STEMI associated with dexamethasone use 4 days following a coronary angiogram with only minor luminal irregularities.

2. Case Presentation

Our patient is a 75-year-old African-American woman with a history of diabetes mellitus, hypertension, hyperlipidemia, and four prior cerebrovascular accidents with mild right sided residual weakness and ventral hernia status after surgical repair. She has no prior history of smoking, alcohol use, illicit drug use, or family history of premature coronary artery disease. She initially presented with shortness of breath, rhinorrhea, and cough productive of yellowish sputum and tested positive for influenza A for which she was started on oseltamivir. On her second day of hospitalization she reported mild retrosternal chest pain accompanied with a Troponin I elevation up to 0.3 ng/mL with an unchanged EKG showing right bundle branch block (RBBB) (Figure 1(a)). She received Aspirin, Clopidogrel, and Heparin drip in addition to Diltiazem and Atorvastatin as treatment for a NSTEMI.

On the following day, she underwent a coronary angiogram revealing only minor luminal irregularities and no significant CAD (Figure 2(a)). Two days later, she underwent nasopharyngolaryngoscopy for progressive dysphonia that showed inflammatory changes of true and false vocal folds, mild granulation changes of the subglottis, and pachydermia. This was deemed secondary to her upper respiratory tract infection and the resulting acute tracheobronchitis. Subsequently, she was started on intramuscular dexamethasone 10 mg Q8 hours.

One day later, she complained of severe retrosternal chest pain with a blood pressure of 90/65 mmHg, heart rate of 95 bpm, and oxygen saturation of 95% on room air. Cardiovascular exam was unremarkable revealing regular heart rate
Figure 1: (a) Baseline EKG with RBBB. (b) EKG showing ST elevation in leads V2–V5. (c) EKG showing resolution of the ST elevation following LAD intervention.

Figure 2: (a) First left heart catheterization showing LAD with minor luminal irregularities. (b) Second left heart catheterization (4 days later) showing the mid-LAD lesion. (c) LAD after intervention.
and normal Sl and S2 with no appreciated murmurs, rubs, or gallop. She had no JVD and clear lungs on auscultation. Distal pulses were well felt without appreciated lower extremity edema. The EKG however showed ST elevation in the anterior leads, V2 to V5 (Figure 1(b)). Bedside echocardiogram revealed a left ventricular ejection fraction (EF) of 30–35% and regional wall motion in the form of apical dyskinesia and severe hypokinesia in the mid to apical anteroseptal, anterior, apical inferior, inferoseptal, and lateral segments. Of note, the pre-MI echocardiogram showed a normal EF with no appreciated regional wall motion abnormalities. The Troponin I level was 0.1 ng/mL (cutoff value of 0.2 ng/mL). She was immediately transferred to the catheterization lab where the angiogram surprisingly revealed a filling defect, likely a thrombus, occluding the midsegment of the LAD (Figure 2(b)). Subsequently, a 2.5 × 18 mm drug eluting stent was deployed with pre- and postballoon dilation resulting in TIMI III flow (Figure 2(c)). Eptifibatide was started in addition to Ticagrelor, Aspirin, Deltiazem, and Atorvastatin. The chest pain resolved shortly after the intervention and the EKG returned to baseline (Figure 1(c)).

Blood work revealed a platelet count of 461k/cumm, hemoglobin of 10.5 mg/dL, and white blood cell count of 9 k/cumm. Homocysteine level was mildly elevated (15.5 micromoles/L, normal range 3.2–10.7). High sensitivity CRP was elevated at 40.9 mg/L. Factor VIII activity (325%, normal range: 63–150), factor XI activity (211%, normal range: 71–124), and thrombin antithrombin complex (13.7 ng/mL, normal range: 0.7–3.2) were all increased while factor VII activity was normal. Fibrinogen level and protein C and S activity were normal. Cardiolipin antibody, JAK2 V617F mutation, and Factor V Leiden were all negative.

3. Discussion

Besides impacting traditional risk factors for CAD such as hypertension (HTN), glucose intolerance, obesity, and hyperlipidemia (HLD), glucocorticoids influence vascular functions, atherogenesis, and remodeling following ischemia or intravascular injury. This influence is mediated by both glucocorticoids and mineralocorticoid receptors and is modified by 11b-hydroxysteroid dehydrogenase enzyme primary metabolism of glucocorticoids [4].

Dexamethasone was shown to promote an atherogenic and hypercoagulable state through different mechanisms. In high doses, it increases Von Willebrand Factor (VWF) which is a prothrombotic marker and increases the platelet activator P-selectin. Moreover, short term use of dexamethasone is a prothrombotic marker and increases the platelet activator XI [5, 6].

In 2014 Okumura et al. reported 3 cases of steroid induced coronary spasm [7]. This might be explained by the fact that, in a dose dependent manner, cortisol treatment decreases ATP-induced intracellular calcium mobilization, which in turn decreases nitrate, nitrite, and nitric oxide release [8]. Similarly, glucocorticoids downregulate cyclooxygenase-1 gene expression and subsequently suppress the production of the vasodilator prostacyclin; meanwhile they increase the synthesis of thromboxane which is a vasoconstrictor [9]. There is also evidence that elevated serum cortisol levels might sensitize the coronary vasoconstricting responses through Rho-kinase activation [10]. Additionally, it reduces endothelial nitric oxide synthase mRNA stability and inhibits the synthesis of tetrahydrobiopterin, which is an important cofactor of endothelial nitric oxide synthase [11].

Interestingly, Okumura hypothesized that corticosteroid-induced vasospastic angina might be underestimated due to being mistakenly confused with its known side effect of epigastric discomfort. Wei et al. reported that, among patients using high dose glucocorticoids (>7.5 mg/day), the relative risk for cardiovascular events occurrence was 2.56 [12].

In 2007, Varas-Lorenzo et al. performed a cohort study with nested case-control analysis to estimate the risk of acute myocardial infarction (AMI) associated with the use of oral corticosteroids by dose and duration. The study included 4795 hospitalized cases of AMI or CAD deaths and randomly sampled 20,000 controls and frequency matched by sex, age, and calendar year.

The adjusted OR for AMI in current users of oral corticosteroids compared to nonusers was 1.42 (95% CI: 1.17–1.72). The risk during the first 30 days of use (OR = 2.24; 95% CI: 1.56–3.20) was greater than with longer duration (OR = 1.22; 95% CI 0.98–1.52). The risk was more pronounced (OR = 2.15; 95% CI 1.45–3.14) among users of prednisolone equivalent doses >10 mg/day. The study concluded that there is a small increased risk of AMI with oral corticosteroid use with a greater risk observed among users of high corticosteroid dose [13].

In 2013, Coloma et al. identified 163 drugs reported to cause acute MI in various case reports, out of which 39 had a more probable association with MI including betamethasone, prednisolone, and dexamethasone (RR (95% confidence interval) 3.2 (2.9, 3.5), OR 1.9 (1.7, 2.2), and IRR 5.4 (4.1, 7.2)). Of note, 285 excess cases representing patients on dexamethasone who had an AMI however with other more plausible causes were identified [3]. All the previous mechanisms might explain a possible “spasm-thrombosis” sequence that occurred in our patient in the setting of her long standing other risk factors including diabetes mellitus, hypertension, and hyperlipidemia as mentioned. Interestingly, two prior cases reported angiographically normal coronaries in androgen using athletes who ended up having a coronary occlusion [14]. We are including a comparison between six prior cases of AMI associated with steroid use shedding the light on their different clinical scenarios and other preexisting risk factors for coronary artery disease (Table 1).

4. Conclusion

Different forms of steroids have been linked to CAD either through promoting its traditional risk factors or by other unidentified mechanisms. In most reported cases of steroid-associated AMI, the temporal relation was the main factor suggesting causality. We believe that, with the wide use of corticosteroids for a variety of indications, physicians should be aware of this possible association. Cautious use should be considered particularly in patients with other risk factors.
Table 1: Comparison between six other cases of MI associated with steroid use.

| Case            | Ferenchick and Aledman [14] | Yildirim et al. [15] | Arslan et al. [16] | Takamatsu et al. [17] | Owecki and Sowiński [18] | Poorzand et al. [2] |
|-----------------|------------------------------|----------------------|-------------------|-----------------------|---------------------------|---------------------|
| Age (years)     | 37                           | 64                   | 20                | 79                    | 66                        | 23                  |
| Risk factors    | Family history of CAD        | HLD                  | Smoking (7 years) | Bortezomib use        | Smoking HLD               |                     |
| Gender          | Male                         | Male                 | Male              | Female                | Female                    | Male                |
| Steroid type    | Nandrolone-decanoate, Boldenone, testosterone-cypionate, Stanozolol, and veterinary oxandrolone | Prednisolone | Methylprednisolone | Dexamethasone | Methylprednisolone | Dexamethasone |
| Indication      | Anabolic steroids (weightlifting) | Idiopathic intracranial HTN (papilledema) | Anaphylaxis | Multiple myeloma | Graves | Anabolic steroids (wrestling) |
| Route           | Intramuscular & oral         | Oral                 | Intravenous       | Intravenous           | Intravenous               | Intramuscular       |
| Dose            | 200 mg/week for 16 weeks     | Oral                 | Intravenous       | Intravenous           | Intravenous               | Intramuscular       |
| Duration of use | Intermittent for 7 years and then 16 weeks before the event | One month | 7 minutes | 5 days | 5 days | 6 months |
Table 1: Continued.

| Case                                      | Ferenchick and Adelman [14] | Yildirim et al. [15] | Arslan et al. [16] | Takamatsu et al. [17] | Owecki and Sowiński [18] | Poorzand et al. [2] |
|-------------------------------------------|-----------------------------|----------------------|-------------------|-----------------------|--------------------------|---------------------|
| Possible confounders                      | Hypotension secondary to anaphylaxis | Bortezomib use       |                   |                       |                          |                     |
| Acute coronary syndrome type              | STEMI                       | NSTEMI and then STEMI few days later | STEMI             | STEMI                 | NSTEMI                   | STEMI               |
| EKG                                       | ST elevation, II, III, and aVF; ST depression, I, aVL | ST elevation, II, III, and aVF; ST depression, I, aVL | ST elevation, II, III, and aVF; ST depression, I, aVL | ST elevation, aVR; ST depression, I, II, and aVF V2–6 | NA                       | ST elevation, I, aVL |
| Echo                                      | Normal                      | Normal               | EF 35% apical & posterolateral wall motion abnormality | EF 68% posterior & anterolateral akinesia | Anteroseptal akinesia   | EF 35% apical, midanterior, anteroseptal akinesia |
| Left heart catheterization findings       | Normal coronaries (3 days following tissue plasminogen activator) | RCA: slow flow and then PDA total occlusion & LAD slow flow | Normal coronaries 10 days later (normal IVUS) (treated with Aspirin & Heparin) | LM/LCX significant lesions LAD mod stenosis | LAD total occlusion RCA critical stenosis | Nonobstructive CAD (4 days after streptokinase) |
| Complications                             |                             |                      |                   |                       |                          | LV thrombus          |
for CAD until there is a larger and more convincing pool of evidence.

**Competing Interests**

The authors have no conflict of interests to disclose.

**References**

[1] M. T. Roe, J. C. Messenger, W. S. Weintraub et al., "Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention," *Journal of the American College of Cardiology*, vol. 56, no. 4, pp. 254–263, 2010.

[2] H. Poorzand, R. Jafarzadeh Esfahani, P. Hosseinzadeh, and M. Vojdanparast, "Acute myocardial infarction in a young male wrestler: a case report," *ARYA Atheroscler*, vol. 11, no. 6, pp. 366–369, 2015.

[3] P. M. Coloma, M. J. Schuemie, G. Trifirò et al., "Drug-induced acute myocardial infarction: identifying ‘prime suspects’ from electronic healthcare records-based surveillance system," *PLoS ONE*, vol. 8, no. 8, article e72148, 2013.

[4] B. R. Walker, "Glucocorticoids and cardiovascular disease," *European Journal of Endocrinology*, vol. 157, no. 5, pp. 545–559, 2007.

[5] B. Jilma, T. Cvitko, A. Winter-Fabry, K. Petroczi, P. Quehenberger, and A. D. Blann, "High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men," *Thrombosis and Haemostasis*, vol. 94, no. 4, pp. 797–801, 2005.

[6] D. J. Brotman, J. P. Girod, A. Posch et al., "Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers," *Thrombosis Research*, vol. 118, no. 2, pp. 247–252, 2006.

[7] W. Okumura, M. Nakajima, R. Tateno, N. Fukuda, and M. Kurabayashi, "Three cases of vasospastic angina that developed following the initiation of corticosteroid therapy," *Internal Medicine*, vol. 53, no. 3, pp. 221–225, 2014.

[8] K. M. Rogers, C. A. Bonar, J. L. Estrella, and S. Yang, "Inhibitory effect of glucocorticoid on coronary artery endothelial function," *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 283, no. 5, pp. H1922–H1928, 2002.

[9] S. S. Jun, Z. Chen, M. C. Pace, and P. W. Shaul, "Glucocorticoids downregulate cyclooxygenase-1 gene expression and prostacyclin synthesis in fetal pulmonary artery endothelium," *Circulation Research*, vol. 84, no. 2, pp. 193–200, 1999.

[10] T. Hizume, K. Morikawa, A. Takaki et al., "Sustained elevation of serum cortisol level causes sensitization of coronary vasoconstricting responses in pigs in vivo: a possible link between stress and coronary vasospasm," *Circulation Research*, vol. 99, no. 7, pp. 767–775, 2006.

[11] T. Wallerath, K. Witte, S. C. Schäfer et al., "Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 23, pp. 13357–13362, 1999.

[12] L. Wei, T. M. MacDonald, and B. R. Walker, "Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease," *Annals of Internal Medicine*, vol. 141, no. 10, pp. 764–770, 2004.

[13] C. Varas-Lorenzo, L. A. G. Rodriguez, A. Maguire, J. Castellsague, and S. Perez-Gutthann, "Use of oral corticosteroids and the risk of acute myocardial infarction," *Atherosclerosis*, vol. 192, no. 2, pp. 376–383, 2007.

[14] G. S. Ferenchick and S. Adelman, "Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter," *American Heart Journal*, vol. 124, no. 2, pp. 507–508, 1992.

[15] U. Yıldırım, O. Gulel, K. Soyulu, S. Yuksel, and M. Sahin, "Steroid-induced recurrent myocardial ischemia," *Revista Portuguesa de Cardiologia (English Edition)*, vol. 33, no. 7-8, pp. 473.e1–473.e4, 2014.

[16] Z. Arslan, A. Iyisoy, and M. Tavlasoglu, "Acute myocardial infarction after prednisolone administration for the treatment of anaphylaxis caused by a wasp sting," *Cardiovascular Journal of Africa*, vol. 24, no. 4, pp. e4–e6, 2013.

[17] H. Takamatsu, T. Yamashita, T. Kotani, A. Sawazaki, H. Okumura, and S. Nakao, "Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma," *International Journal of Hematology*, vol. 91, no. 5, pp. 903–906, 2010.

[18] M. Owecki and J. Sowiński, "Acute myocardial infarction during high-dose methylprednisolone therapy for Graves’ ophthalmopathy," *Pharmacy World and Science*, vol. 28, no. 2, pp. 73–75, 2006.